Estados Unidos · Plataformas y datos · The Motley Fool

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

Publicado por The Motley Fool · Estados Unidos hace 34 min

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? — Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027? · The Motley Fool

Resumen detallado

Bristol Myers trades at under 10 times forward earnings, while Vertex commands nearly triple that multiple, but its margins are roughly double.

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

También te puede interesar

How much in Roth conversions can you do in 2027 with the new tax brackets?

Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline

Heavy rain floods tents housing Gaza displaced people, aid shortages hamper response

Best Stocks Under $5

Just 13.8% of American Families Own a Second Home or Other Residential Property. The Typical One Is Worth $280,000

Fed rate call leaves stock investors watching December closely